Kernal Biologics, Inc. announced it raised $500,000 in an initial filing from an offering of $1 Million

Company

Location

About

Kernal Bio is a venture-backed therapeutics company engineering cells inside the body using AI-designed, selective mRNA and targeted LNP technology. By developing in vivo CAR-T therapies, Kernal Bio is advancing precision treatments for autoimmune diseases and blood cancers. The company was founded by experts from MIT, Harvard, Merck, and BMS, and its leadership team brings a track record of three FDA-approved therapies and over 120 patents. With support from leading investors — including Hummingbird Ventures, Amgen Ventures, Y Combinator, FoundersX, and HBM — Kernal Bio is transforming the future of cell therapy design and delivery.